Trial Profile

Expanded access use of TKM-Ebola in patients with confirmed or suspected Ebola virus infections

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Nov 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TKM Ebola (Primary)
Indications Ebola virus infections
Focus Expanded access; Therapeutic Use
Sponsors Arbutus Biopharma

Most Recent Events

11 Nov 2014 New trial record
21 Oct 2014 To date, several patients have been treated under this protocol and data collected will be provided to the FDA, according to a Tekmira Pharmaceuticals Corporation media release.
22 Sep 2014 The US FDA and Canada Health have authorised Tekmira to provide TKM-Ebola for treatment under expanded access protocols to subjects with confirmed or suspected Ebola virus infections, according to a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com